H1N1 News and Research RSS Feed - H1N1 News and Research Twitter

Novel influenza A (H1N1) is a new flu virus of swine origin that was first detected in Mexico and the United States in March and April, 2009. The first novel H1N1 patient in the United States was confirmed by laboratory testing at CDC on April 15, 2009. The second patient was confirmed on April 17, 2009. It was quickly determined that the virus was spreading from person-to-person. On April 22, CDC activated its Emergency Operations Center to better coordinate the public health response. On April 26, 2009, the United States Government declared a public health emergency.

It’s thought that novel influenza A (H1N1) flu spreads in the same way that regular seasonal influenza viruses spread; mainly through the coughs and sneezes of people who are sick with the virus.
UTMB experts honored with Lifetime Achievement Award for contributions to study of deadly diseases

UTMB experts honored with Lifetime Achievement Award for contributions to study of deadly diseases

The global experts who study the deadliest infectious diseases recognized the contributions of Frederick A. Murphy and Thomas G. Ksiazek, professors at the University of Texas Medical Branch, with a Lifetime Achievement Award at the 6th annual International Symposium on Filoviruses. The filoviruses include Ebola and Marburg viruses that cause death in 50 to 90 percent of people infected. The current outbreak of Ebola virus raging in West Africa has caused more than 100 deaths so far. [More]
Findings pave way for potential therapy to combat H1N1 flu virus

Findings pave way for potential therapy to combat H1N1 flu virus

Flu epidemics cause up to half a million deaths worldwide each year, and emerging strains continually threaten to spread to humans and cause even deadlier pandemics. A study by McGill University professor Maziar Divangahi published by Cell Press on April 10 in the journal Immunity reveals that a drug that inhibits a molecule called prostaglandin E2 (PGE2) increases survival rates in mice infected with a lethal dose of the H1N1 flu virus. [More]
Guidance on use of Tamiflu needs to be reviewed in light of most recent evidence

Guidance on use of Tamiflu needs to be reviewed in light of most recent evidence

Tamiflu (the antiviral drug oseltamivir) shortens symptoms of influenza by half a day, but there is no good evidence to support claims that it reduces admissions to hospital or complications of influenza. [More]
PeptiDream develops novel macrocyclic peptide inhibitor for treatment of multiple influenza strains

PeptiDream develops novel macrocyclic peptide inhibitor for treatment of multiple influenza strains

PeptiDream Inc., a public Tokyo-based biopharmaceutical company ("PeptiDream")( TOKYO:4587) announced today, in collaboration with The Tokyo Metropolitan Institute of Medical Science ("Tokyo Metropolitan Institute") the discovery and development of a novel macrocyclic peptide inhibitor for the treatment of multiple influenza strains. [More]
EPFL scientists develop computer tool to identify mutations that make influenza resistant to Tamiflu

EPFL scientists develop computer tool to identify mutations that make influenza resistant to Tamiflu

Tamiflu is one of the few available treatments for those who come down with the flu. But the virus quickly develops resistance; multiplying at a rate of several generations a day, these tiny pathogens rapidly accumulate genetic mutations. Because of this, they have a good chance of developing counterattacks to the antiviral. How can these infinitesimal variations be identified within the immensity of the virus' genetic code? EPFL researchers have created a computer tool that can shed light on the flu virus' formidable adaptability. [More]
Tamiflu cuts H1N1 pandemic deaths by 25%, shows study

Tamiflu cuts H1N1 pandemic deaths by 25%, shows study

Adults hospitalised with H1N1 influenza during the 2009–2010 pandemic were 25% less likely to die from the disease if they were given antiviral drugs called neuraminidase inhibitors (NAIs) such as Tamiflu, according to a large meta-analysis involving more than 29 000 patients from 38 countries, published in The Lancet Respiratory Medicine journal. The findings also indicate that treatment within 2 days of flu symptoms developing halved the risk of death compared with later treatment or no treatment. [More]

Study shows only 23% of seasonal and pandemic flu caused symptoms

Around 1 in 5 of the population were infected in both recent outbreaks of seasonal flu and the 2009 H1N1 influenza pandemic, but just 23% of these infections caused symptoms, and only 17% of people were ill enough to consult their doctor. [More]
Scientists map key elements of immune overreaction triggered by influenza virus infection

Scientists map key elements of immune overreaction triggered by influenza virus infection

Scientists at The Scripps Research Institute (TSRI) have mapped key elements of a severe immune overreaction—a "cytokine storm"—that can both sicken and kill patients who are infected with certain strains of flu virus. [More]
CDC report reveals that younger age group is mostly hit by flu this season

CDC report reveals that younger age group is mostly hit by flu this season

This influenza season was particularly hard on younger- and middle-age adults, the Centers for Disease Control and Prevention reported in today's Morbidity and Mortality Weekly Report. [More]

Upstream interventions may provide options to contain emerging pathogens at source

While many endemic infectious diseases of humans have been largely contained, new microbes continue to emerge to threaten human and animal health. [More]

Study provides comprehensive analysis of the evolutionary relationships of influenza virus

A new study reconstructing the evolutionary tree of flu viruses challenges conventional wisdom and solves some of the mysteries surrounding flu outbreaks of historical significance. [More]

Unvaccinated flu patients need more intensive care

A snapshot of patients who required care at Duke University Hospital during this year's flu season shows that those who had not been vaccinated had severe cases and needed the most intensive treatment. [More]
CDC recommends effective tips to help families stay healthy during peak flu activity

CDC recommends effective tips to help families stay healthy during peak flu activity

With outbreaks of cold and flu on the rise across the U.S., Americans are facing a seemingly impossible task of helping their families stay healthy this winter. As of last week, the U.S. Centers for Disease Control and Prevention (CDC) reported that 47 states have declared the incidence of flu to be regional or widespread in their communities and nearly 10,000 cases of H1N1 have been documented. [More]
Swedish study confirms H1N1 vaccinations show increased risk of narcolepsy in children, adolescents

Swedish study confirms H1N1 vaccinations show increased risk of narcolepsy in children, adolescents

Pandemrix is an influenza vaccination, created in 2009 to combat H1N1, known as Swine Flu. Now, a team of Swedish clinicians testing the vaccine for links to immune-related or neurological diseases have linked Pandemrix to an increased risk of narcolepsy in young adults. [More]
Vivaldi Biosciences inks agreement with NIAID to evaluate LAIV candidates against influenza A

Vivaldi Biosciences inks agreement with NIAID to evaluate LAIV candidates against influenza A

Vivaldi Biosciences Inc., a clinical-stage biotechnology company developing live attenuated influenza vaccines against seasonal and pandemic influenza, today announced that it has signed a Cooperative Research and Development Agreement with the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, to generate and evaluate in preclinical studies LAIV candidates against influenza A(H7N9). [More]
Three skilled nursing centers in Texas to provide free flu shots to seniors

Three skilled nursing centers in Texas to provide free flu shots to seniors

Colonial Manor Cleburne, Advanced Healthcare of Garland and Winfield Rehab and Nursing, top-notch rehabilitation and skilled nursing centers, located in Cleburne, Garland, and Crockett, Texas, will be providing free flu shots to seniors 65 and above on January 22, 23 & 27 2014 from 10 AM - 2 PM. [More]

Study suggests effective way to counter influenza infections

McGill researchers, led by Dr. Maya Saleh of the Department of Medicine, have identified an enzyme, cIAP2 that helps the lungs protect themselves from the flu by giving them the ability to resist tissue damage. "It's a discovery that offers exciting new avenues for controlling influenza, since until now attempts to target the virus itself have proven challenging, especially in the face of emerging new strains of the virus," says Saleh, who is also a researcher at the Research Institute of the McGill University Health Centre. [More]
Study indicates some groups have specific genetic make-up that prevents from fighting off influenza

Study indicates some groups have specific genetic make-up that prevents from fighting off influenza

Research indicated that some Indigenous people such as in Alaska and Australia displayed limited immunity response to the effects of influenza. [More]

Meridian's TRU FLU assay gets FDA clearance for analytical sensitivity claim for avian Influenza H7N9 strain

Meridian Bioscience, Inc. today announced that the company's TRU FLU assay received FDA clearance for an analytical sensitivity claim for the novel avian Influenza H7N9 strain, A/Anhui/1/2013. TRU FLU is a rapid immunoassay that detects influenza A and influenza B viruses in 15 minutes in human respiratory specimens. [More]
CEL-SCI closes public offering of common stock, exercises over-allotment option to purchase additional shares

CEL-SCI closes public offering of common stock, exercises over-allotment option to purchase additional shares

CEL-SCI Corporation, a late-stage oncology company, today announced that it has closed an underwritten public offering of units consisting of an aggregate of 5,238,095 shares of common stock and warrants to purchase an aggregate of 5,238,095 shares of common stock. The [More]